Product NDC: | 0185-0749 |
Proprietary Name: | Carisoprodol, Aspirin and Codeine Phosphate |
Non Proprietary Name: | Carisoprodol, Aspirin and Codeine Phosphate |
Active Ingredient(s): | 325; 200; 16 mg/1; mg/1; mg/1 & nbsp; Carisoprodol, Aspirin and Codeine Phosphate |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0185-0749 |
Labeler Name: | Eon Labs, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA040118 |
Marketing Category: | ANDA |
Start Marketing Date: | 19960416 |
Package NDC: | 0185-0749-10 |
Package Description: | 1000 TABLET in 1 BOTTLE (0185-0749-10) |
NDC Code | 0185-0749-10 |
Proprietary Name | Carisoprodol, Aspirin and Codeine Phosphate |
Package Description | 1000 TABLET in 1 BOTTLE (0185-0749-10) |
Product NDC | 0185-0749 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Carisoprodol, Aspirin and Codeine Phosphate |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 19960416 |
Marketing Category Name | ANDA |
Labeler Name | Eon Labs, Inc. |
Substance Name | ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE |
Strength Number | 325; 200; 16 |
Strength Unit | mg/1; mg/1; mg/1 |
Pharmaceutical Classes | Centrally-mediated Muscle Relaxation [PE],Muscle Relaxant [EPC],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Full Opioid Agonists [MoA],Opioid Agonist [EPC] |